Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET.
about
Diagnostic procedures for submucosal tumors in the gastrointestinal tract.Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial.Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma.Neurotensin receptor 1 is expressed in gastrointestinal stromal tumors but not in interstitial cells of Cajal.Preclinical efficacy of the c-Met inhibitor CE-355621 in a U87 MG mouse xenograft model evaluated by 18F-FDG small-animal PET.Therapeutic procedures for submucosal tumors in the gastrointestinal tract.Clinical practice guideline for accurate diagnosis and effective treatment of gastrointestinal stromal tumor in KoreaImaging gastrointestinal stromal tumors.Surgical management of gastric gastrointestinal stromal tumor: a single center experience.Early decline in serum phospho-CSE1L levels in vemurafenib/sunitinib-treated melanoma and sorafenib/lapatinib-treated colorectal tumor xenografts.Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO.(18)F-FDG PET in sarcoma treatment response imaging.Molecular imaging: what can be used today.Positron emission tomography: clinical applications in oncology. Part 2.Imatinib as preoperative therapy in Chinese patients with recurrent or metastatic GISTs.Small molecule signal transduction inhibitors for the treatment of solid tumors.Gastrointestinal stromal tumours: a series of 12 casesPromises and challenges of positron emission tomography for assessment of sarcoma in daily clinical practice.The use of positron emission tomography in soft tissue sarcoma patients under therapy with trabectedin.PET imaging for Treatment Response in CancerClinical applications of positron emission tomography in sarcoma management.F-FDG PET Imaging in the Evaluation of Treatment Response to New Chemotherapies beyond Imatinib for Patients with Gastrointestinal Stromal Tumors.Imaging modalities of gastrointestinal stromal tumors.Surveillance strategies for gastrointestinal stromal tumors.FDG PET and FDG PET/CT in patients with gastrointestinal stromal tumours.The value of (18) F-fluorodeoxyglucose positron emission tomography for prediction of treatment response in gastrointestinal stromal tumors: a systematic review and meta-analysis.CAS (CSE1L) signaling pathway in tumor progression and its potential as a biomarker and target for targeted therapy.Positron emission tomography as a surrogate marker for evaluation of treatment response in patients with desmoid tumors under therapy with imatinib.Imatinib analogs as potential agents for PET imaging of Bcr-Abl and c-KIT expression at a kinase level.Insulin-like growth factors and insulin-like growth factor-binding proteins in relation to disease status and incidence of hypoglycaemia in patients with a gastrointestinal stromal tumour.Early prediction of therapy outcome in patients with high-risk soft tissue sarcoma using positron emission tomography.Imaging therapy response of gastrointestinal stromal tumors (GIST) with FDG PET, CT and MRI: a systematic review.Xanthogranulomatous gastritis mimicking malignant GIST on F-18 FDG PET.CT scan is not everything in the evaluation of a patient with gastrointestinal tumors (GIST) under imatinib therapy.Clinical practice guideline for accurate diagnosis and effective treatment of gastrointestinal stromal tumor in Korea.Gastrointestinal Stromal Tumors of the Distal Gastrointestinal Tract
P2860
Q30430242-E147F138-B68F-4A20-9109-3F70414F96D0Q33561602-F01659A8-9E21-45B8-848A-1BFB86FE4F36Q33780956-A9F56FB9-F20D-48BA-BB3C-C0B6A73F5443Q33833577-706121AF-E598-4EC3-85E4-58364CAEC830Q34164758-E95F33AA-A49F-48CF-BFAE-916019FF28FAQ34233024-30B573F1-F940-49AD-9BDF-46E30047255CQ34255550-60A25148-04F2-4668-A24E-51FE34937106Q34414114-B2DCF2D8-0104-4294-9A1A-AD774EA86E31Q35064922-52B7A2AD-1275-4DAA-83B3-617D81F073DFQ35743289-B29C3EBF-11DA-4267-9D5E-94F2A03A046DQ36076570-AD49A5EA-875D-4335-A282-442C641AF3D4Q36337223-017FAA52-2212-4A28-A29F-0181A7961158Q36345342-DD4B3656-2589-40D6-8DDD-231C23FA7505Q36448703-CDFA8D46-CD23-4EE5-98E4-2812DFDA94ECQ36563238-A67613EE-DEDF-41A4-82F9-F43B25BE7234Q36895413-0CA6535C-8FBA-4126-9723-E61B4FB53CF8Q36956330-3B4C55CC-089B-4BEA-8DB4-52AE497FF536Q36971711-15120FA8-EA58-4FB8-9882-367B5F165C5DQ37389930-D0B99C43-3956-47DE-8462-251CB966337CQ37465205-FC3BE224-4021-4511-84D4-38930A298D00Q37845828-6D98D2F3-65CE-431F-A1EA-C01E3487C4C6Q37944803-4FE7341D-0D7A-4C33-AFE9-4B6FA9847437Q37954208-13A9EC8D-1F4B-488F-B843-35C8DFD8D7CAQ37954209-2B842569-564E-4DA6-9608-2F01E5FA81A5Q38034434-49E530C8-C624-42DA-8AF5-9F288A4D37D8Q38661189-17173F03-099E-4E78-94CC-D41971014E37Q38946743-6A516AC8-2921-4824-8D45-C07685EA17C2Q41462626-AE0845FF-606D-4DEC-9A3A-5BEB6A13BABFQ41890733-7858C819-02A7-4DB5-8A7E-436CED1BB886Q46093021-7B3DFB70-1492-4147-AE67-0D9B15179D39Q46716785-8EB8DA99-6BEB-4D96-A320-E1A04D1AD880Q47097647-100F8AF8-EAD3-4D3F-AD91-77D8ADA2771CQ53154396-E2FC12AD-33B4-4E39-877F-0BAF38227075Q53201946-361EA4A8-BF30-47C9-A80C-7CB383B75A62Q55375821-26F55FDD-ABB2-40A5-8995-E27407794222Q57162992-27821C5B-9DB6-4A00-8F5C-7ED25CAE3FA0
P2860
Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Imatinib mesylate for the trea ...... : best monitored with FDG PET.
@en
Imatinib mesylate for the trea ...... : best monitored with FDG PET.
@nl
type
label
Imatinib mesylate for the trea ...... : best monitored with FDG PET.
@en
Imatinib mesylate for the trea ...... : best monitored with FDG PET.
@nl
prefLabel
Imatinib mesylate for the trea ...... : best monitored with FDG PET.
@en
Imatinib mesylate for the trea ...... : best monitored with FDG PET.
@nl
P1476
Imatinib mesylate for the trea ...... : best monitored with FDG PET.
@en
P2093
Pieter L Jager
Winette T A van der Graaf
P304
P356
10.1097/00006231-200405000-00002
P577
2004-05-01T00:00:00Z